Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1 mg/kg + ipilimumab 3 mg/kg expansion from CheckMate 032

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 29; p. viii725
Main Authors Rosenberg, J.E., Sharma, P., de Braud, F.G.M., Basso, U., Calvo, E., Bono, P., Morse, M., Ascierto, P.A., Lopez-Martin, J.A., Brossart, P., Rohrberg, K.S., Reguart, N., Lin, W.H., Meadows-Shropshire, S., Saci, A., Callahan, M., Siefker-Radtke, A.O.
Format Journal Article
LanguageEnglish
Published 01.10.2018
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
DOI:10.1093/annonc/mdy424.038